The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 3

Meta-analysis of grade 3-4 adverse events.

Adverse event	Events in intervention arm	Events in control arm	RR (95% CI)
Neutropenia	93/462	139/453	0.66(0.52-0.82)	0.000
Thrombocytopenia	71/462	13/453	5.36(3.01-9.53)	0.000
Anemia	53/462	5/453	10.39(4.19-25.76)	0.000
Febrile neutropenia	7/462	14/453	0.49(0.20-1.20)	0.120
Fatigue	39/462	11/453	3.48(1.80-6.70)	0.000
Hypertension	24/462	30/453	0.78(0.47-1.32)	0.361
Overall	340/462	250/453	1.59(1.07-2.36)	0.022